The US Food and Drug Administration (HKG:9926) approved Akeso's penpulimab-kcqx combination with cisplatin or carboplatin and gemcitabine for the treatment of nasopharyngeal carcinoma.
The drug, a differentiated PD-1 monoclonal antibody, is indicated for the treatment of recurrent or metastatic non-keratinizing nasopharyngeal carcinoma in adults, according to a Friday filing with the Hong Kong bourse.
Chinese authorities have already approved the drug for first-line treatment of advanced nasopharyngeal carcinoma and second or later-line treatment of advanced nasopharyngeal carcinoma, the filing said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。